



INFORMATION DISCLOSURE STATEMENT

Applicant : Goddard, et al.
App. No : 10,063,557
Filed : May 2, 2002
For : SECRETED AND
TRANSMEMBRANE POLYPEPTIDES
AND NUCLEIC ACIDS ENCODING
THE SAME
Examiner : David J. Blanchard
Art Unit : 1642

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

March 18, 2005

(Date)

Daniel Hart, Reg. No. 40,637

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is an Information Disclosure Statement by Applicant (PTO/SB/08 equivalent) listing twenty-two (22) references to be considered by the Examiner. Also enclosed are eighteen (18) foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed with an RCE no fee is required. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: March 18, 2005By: Daniel Hart

Daniel Hart
Registration No. 40,637
Attorney of Record
Customer No. 30,313
(619) 235-8550

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Multiple sheets used when necessary)

SHEET 1 OF 2

Application No.	10/063,557
Filing Date	May 2, 2002
First Named Inventor	Goddard, et al.
Art Unit	1642
Examiner	David J. Blanchard
Attorney Docket No.	GNE.3230R1C39

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	5,407,799	04-18-1995	Studier	
	2	6,498,235 B2	12-24-2002	Sheppard, et al.	
	3	6,645,499 B1	11-11-2003	Lal, et al.	
	4	6,730,502 B2	05-04-2004	Van Hijum, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	5	ALBERTS, et al. 2002. <i>Molecular Biology of the Cell 4th Edition</i> , pp. 302, 363-364, 379, 435. New York: Garland Publishing.	
	6	The 1991 Boehringer Mannheim Biochemicals Catalog, page 557, 1991.	
	7	BURGESS, et al. 1990. Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue. <i>The Journal of Cell Biology</i> , 111:2129-2138.	
	8	GRIMALDI, et al. 1989. The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene. <i>Blood</i> , 73(8):2081-2085.	
	9	HANNA, et al. Aug. 1999. HER-2/neu breast cancer predictive testing. <i>Pathology Associates Medical Laboratories</i> .	

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No. 10/063,557
 Filing Date May 2, 2002
 First Named Inventor Goddard, et al.
 Art Unit 1642
 Examiner David J. Blanchard
 Attorney Docket No. GNE.3230R1C39

(Multiple sheets used when necessary)

SHEET 2 OF 2

MAR 22 2005

NON PATENT LITERATURE DOCUMENTS

Initials	Date No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	10	HAYNES, et al. 1998. Proteome analysis: Biological assay or data archive? <i>Electrophoresis</i> , 19:1862-1871.	
	11	HU, et al. 2003. Analysis of genomic and proteomic data using advanced literature mining. <i>Journal of Proteome Research</i> , 2:405-412.	
	12	HYMAN, et al. 2002. Impact of DNA amplification on gene expression patterns in breast cancer. <i>Cancer Research</i> , 62:6240-6245.	
	13	LAZAR, et al. 1988. Transforming growth factor α : Mutation of aspartic acid 47 and leucine 48 results in different biological activities. <i>Molecular and Cellular Biology</i> , 8(3):1247-1252.	
	14	LI, et al. 1980. β -Endorphin omission analogs: Dissociation of immunoreactivity from other biological activities. <i>Proc. Natl. Acad. Sci. USA</i> , 77(6):3211-3214.	
	15	LIN, et al. 1975. Structure-function relationships in glucagon: Properties of highly purified Des-His ¹ -, Monoiodo-, and [Des-Asn ²⁸ , Thr ²⁹](homoserine lactone ²⁷)-glucagon. <i>Biochemistry</i> , 14(8):1559-1563.	
	16	MEEKER, et al. 1990. Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia. <i>Blood</i> , 76(2):285-289.	
	17	MERIC, et al. 2002. Translation initiation in cancer: A novel target for therapy. <i>Molecular Cancer Therapeutics</i> , 1:971-979.	
	18	ØRNTØFT, et al. 2002. Genome-wide study of gene copy numbers, transcripts, and protein levels in pairs of non-invasive and invasive human transitional cell carcinomas. <i>Molecular & Cellular Proteomics</i> , 1:37-45.	
	19	POLLACK, et al. 2002. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. <i>PNAS</i> , 99(20):12963-12968.	
	20	SCHWARTZ, et al. 1987. A superactive insulin: [B10-aspartic acid]insulin(human). <i>Proc. Natl. Acad. Sci. USA</i> , 84:6408-6411.	
	21	SINGLETON, et al. 1992. Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene. <i>Pathol. Annu.</i> , 1(27):165-190.	
	22	ZHIGANG, et al. 2004. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer. <i>World Journal of Surgical Oncology</i> , 2:13.	

1351252_1:dmb
031805

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.